Ascendis presents data from phase II trial of rare hormone disease treatment

Danish Ascendis Pharma has announced week-84 data from its TransCon PTH product study within the rare endocrine disorder hypoparathyroidism.

Photo: Kevin Grønnemann / MedWatch

Ascendis Pharma, which is based in Denmark, is ready to present top-line results from week 84 of its phase II trial with its drug candidate Transcon PTH against the rare endocrine disorder hypoparathyroidism, which affects the level of parathyroid hormone in patients, it reports in a press release.

The drug's safety, tolerability and efficacy in adult patients were tested in the study.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Further reading

Related articles

Latest news

See all jobs